AbbVie Inc. $ABBV Holdings Cut by Bokf Na

Key Points

• Bokf Na trimmed its AbbVie stake by 3.4% in Q3, selling 8,422 shares and now owning 237,009 shares worth $54.877 million, making AbbVie 0.8% of its portfolio and its 25th largest holding.
• AbbVie beat quarterly estimates with EPS of $2.71 (vs. $2.65 expected) and revenue of $16.62 billion (+10% YoY), and set FY2026 guidance of 14.370–14.570 EPS (Q1 guidance 2.970–3.010).
• Dividend and sentiment risks: AbbVie declared a quarterly dividend of $1.73 ($6.92 annualized, ~3.0% yield) but has a high payout ratio (293%), while recent insider selling and a competitive loss for Skyrizi have raised governance and growth concerns.

Bokf Na trimmed its holdings in AbbVie Inc. (NYSE:ABBV - Free Report) by 3.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 237,009 shares of the company's stock after selling 8,422 shares during the quarter. AbbVie comprises 0.8% of Bokf Na's portfolio, making the stock its 25th largest holding. Bokf Na's holdings in AbbVie were worth $54,877,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of ABBV. Evolution Wealth Management Inc. acquired a new position in shares of AbbVie in the 2nd quarter worth $26,000. Caitlin John LLC purchased a new position in AbbVie in the 3rd quarter worth about $33,000. Redmont Wealth Advisors LLC acquired a new stake in AbbVie during the 3rd quarter worth about $41,000. Financial Gravity Companies Inc. acquired a new position in shares of AbbVie in the second quarter worth about $36,000. Finally, Delos Wealth Advisors LLC acquired a new stake in shares of AbbVie during the second quarter valued at approximately $39,000. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Trading Up 0.3%

Shares of ABBV opened at $227.58 on Thursday. The company's fifty day simple moving average is $224.58 and its 200 day simple moving average is $224.47. AbbVie Inc. has a 1-year low of $164.39 and a 1-year high of $244.81. The company has a market cap of $402.40 billion, a price-to-earnings ratio of 96.43, a PEG ratio of 0.79 and a beta of 0.34.

AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.65 by $0.06. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The company had revenue of $16.62 billion during the quarter, compared to analysts' expectations of $16.39 billion. During the same period last year, the firm posted $2.16 earnings per share. The business's revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, research analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 3.0%. The ex-dividend date is Wednesday, April 15th. AbbVie's dividend payout ratio (DPR) is 293.22%.

Insiders Place Their Bets

In related news, EVP Perry C. Siatis sold 22,381 shares of the company's stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the sale, the executive vice president directly owned 38,137 shares in the company, valued at $8,771,510. This represents a 36.98% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP David Ryan Purdue sold 5,230 shares of the firm's stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the transaction, the senior vice president directly owned 2,654 shares of the company's stock, valued at approximately $619,868.24. This represents a 66.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.25% of the stock is currently owned by company insiders.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Elahere market opportunity highlighted — A market research report reiterates growing epidemiology and adoption tailwinds for Elahere (mirvetuximab soravtansine), supporting long-term revenue upside for AbbVie’s oncology franchise. Elahere Market Report
• Positive Sentiment: Obesity program visibility — Coverage noting AbbVie (with partner Regeneron) showcased obesity data, which keeps investor focus on higher-growth cardiometabolic opportunities beyond legacy immunology products. BiopharmaDive article
• Neutral Sentiment: Phase I ABBV‑295 topline reported — AbbVie released topline data from its ABBV‑295 Phase I study; investors will watch detailed readouts and next‑step decisions for any meaningful share‑price impact. Topline ABBV‑295 report
• Neutral Sentiment: Leerink conference presentation — Management provided updates at the Leerink Global Healthcare Conference; these transcripts supply incremental detail but no blockbuster surprises were flagged in headlines. Leerink transcript
• Neutral Sentiment: Citi keeps Hold rating — Analyst Geoff Meacham maintained a Hold and $230 PT, signaling limited near‑term upside in street estimates despite pipeline promise. TipRanks/Citi note
• Neutral Sentiment: Sector tailwinds — Commentators (Josh Brown, others) argue large‑cap biotech is resilient to disruption, which can buoy AbbVie as a defensive growth biotech holding. Josh Brown/sector view
• Negative Sentiment: Skyrizi lost in psoriatic arthritis trial — UCB’s Bimzelx outperformed AbbVie’s Skyrizi in a head‑to‑head psoriatic arthritis study, raising competitive risk for a core immunology franchise and putting pressure on future Skyrizi sales growth. Seeking Alpha: Skyrizi vs Bimzelx
• Negative Sentiment: Coverage: UCB victory emphasized — Trade press picked up the Bimzelx win, amplifying market concern about competitive erosion in AbbVie’s immunology portfolio. FiercePharma coverage
• Negative Sentiment: Insider selling headline — Reports of insider selling (small headline move) can weigh on sentiment and were cited as a driver of a near‑term pullback. Insider selling report
• Negative Sentiment: CEO pay increase draws attention — A sizeable pay bump for CEO Robert Michael may raise governance concerns among some investors. CEO pay article

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Wall Street Zen upgraded AbbVie from a "buy" rating to a "strong-buy" rating in a report on Saturday, February 28th. HSBC upgraded AbbVie from a "hold" rating to a "buy" rating and boosted their price target for the company from $225.00 to $265.00 in a research note on Wednesday, December 10th. BMO Capital Markets restated an "outperform" rating on shares of AbbVie in a research note on Monday. Evercore dropped their price objective on AbbVie from $232.00 to $228.00 and set an "outperform" rating for the company in a research note on Wednesday, February 4th. Finally, Citigroup reduced their price target on shares of AbbVie from $235.00 to $230.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 27th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat, AbbVie has an average rating of "Moderate Buy" and a consensus price target of $253.15.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.